[1] 中国医师协会外科医师分会甲状腺外科医师委员会, 中国研究型医院学会甲状腺疾病专业委员会, 中国医疗保健国际交流促进会临床实用技术分会.  甲状腺功能亢进症外科治疗中国专家共识(2020版)[J]. 中国实用外科杂志, 2020, 40(11): 1229-1233.   doi: 10.19538/j.cjps.issn1005-2208.2020.11.01
Chinese Thyroid Association, Chinese Collage of Surgeons, Chinese Medical Doctor Association, Chinese Research Hospital Association Thyroid Disease Committee, Clinical Practical Technology Committee of China International Exchange and Promotive Association for Medical and Health Care.  Chinese expert consensus on surgical treatment of hyperthyroidism (2020 edition)[J]. Chin J Pract Surg, 2020, 40(11): 1229-1233.   doi: 10.19538/j.cjps.issn1005-2208.2020.11.01
[2] Li YZ, Teng D, Ba JM, et al.  Efficacy and safety of long-term universal salt iodization on thyroid disorders: epidemiological evidence from 31 provinces of mainland China[J]. Thyroid, 2020, 30(4): 568-579.   doi: 10.1089/thy.2019.0067
[3] 邢岩.  放射性核素碘131治疗Graves甲状腺功能亢进的研究进展[J]. 上海医药, 2021, 42(14): 3-6.   doi: 10.3969/j.issn.1006-1533.2021.14.002
Xing Y.  Research progress of radionuclide 131 iodine in the treatment of Graves hyperthyroidism[J]. Shanghai Med Pharm J, 2021, 42(14): 3-6.   doi: 10.3969/j.issn.1006-1533.2021.14.002
[4] 中华医学会核医学分会.  131I治疗格雷夫斯甲亢指南(2021版)[J]. 中华核医学与分子影像杂志, 2021, 41(4): 242-253.   doi: 10.3760/cma.j.cn321828-20201109-00405
Chinese Society of Nuclear Medicine.  Clinical guidelines for 131I treatment of Graves' hyperthyroidism (2021 edition)[J]. Chin J Nucl Med Mol Imaging, 2021, 41(4): 242-253.   doi: 10.3760/cma.j.cn321828-20201109-00405
[5]

国家卫生健康委员会. GBZ 120−2020核医学放射防护要求[S]. 北京: 中国标准出版社, 2020.

National Health Commission of the People's Republic of China. GBZ 120−2020 requirements for radiological protection in nuclear medicine[S]. Beijing: Standards Press of China, 2020.
[6] 甘景文.  碘131和抗甲状腺药物治疗甲状腺功能亢进症的进展[J]. 中外医学研究, 2020, 18(18): 178-180.   doi: 10.14033/j.cnki.cfmr.2020.18.074
Gan JW.  Progress of iodine 131 and antithyroid drugs in the treatment of hyperthyroidism[J]. Chin Foreign Med Res, 2020, 18(18): 178-180.   doi: 10.14033/j.cnki.cfmr.2020.18.074
[7] Canto AU, Dominguez PN, Jimeno CA, et al.  Comparison of fixed versus calculated activity of radioiodine for the treatment of Graves disease in adults[J]. Endocrinol Metab (Seoul), 2016, 31(1): 168-173.   doi: 10.3803/EnM.2016.31.1.168
[8]

王荣福, 安锐. 核医学[M]. 北京: 人民卫生出版社, 2018.

Wang RF, An R. Nuclear medicine[M]. Beijing: People's Medical Publishing House, 2018.
[9] 凌攀, 倪红珍, 杨柳莹, 等.  2014−2018年四川省从事放射性工作人员染色体畸变率分析[J]. 预防医学情报杂志, 2019, 35(11): 1290-1293.
Ling P, Ni HZ, Yang LY, et al.  Analysis on chromosome aberration rate of radioactive practitioners in Sichuan Province from 2014 to 2018[J]. J Prev Med Inf, 2019, 35(11): 1290-1293.
[10] 姚叶豹, 马得勋, 殷爱民, 等.  低剂量电离辐射对人体健康影响的研究现状[J]. 辐射防护通讯, 2020, 40(3): 1-8, 24.   doi: 10.3969/j.issn.1004-6356.2020.03.001
Yao YB, Ma DX, Yin AM, et al.  Research progress on effects of low dose ionizing radiation on human health[J]. Radiat Prot Bull, 2020, 40(3): 1-8, 24.   doi: 10.3969/j.issn.1004-6356.2020.03.001
[11] Kamiya K, Ozasa K, Akiba S, et al.  Long-term effects of radiation exposure on health[J]. Lancet, 2015, 386(9992): 469-478.   doi: 10.1016/S0140-6736(15)61167-9
[12] 王萧, 焦玲, 张桂芝, 等.  甲亢患者碘治疗后131I滞留量与周围剂量当量率的关系[J]. 辐射研究与辐射工艺学报, 2015, 33(5): 050203-.   doi: 10.11889/j.1000-3436.2015.rrj.33.050203
Wang X, Jiao L, Zhang GZ, et al.  Study on retained body activity and external dose rate of patients receiving 131I therapy for hyperthyroidism[J]. J Radiat Res Radiat Process, 2015, 33(5): 050203-.   doi: 10.11889/j.1000-3436.2015.rrj.33.050203
[13] Liu B, Tian R, Peng WA, et al.  Radiation safety precautions in 131I therapy of Graves' disease based on actual biokinetic measurements[J]. J Clin Endocrinol Metab, 2015, 100(8): 2934-2941.   doi: 10.1210/jc.2015-1682
[14]

ICRP. Release of patients after therapy with unsealed radionuclides[R]. ICRP Publication 94, Amsterdam: Elsevier, 2004.
[15] 张晓懿, 涂彧.  甲亢患者131I治疗后人体周围辐射场剂量分布[J]. 中国辐射卫生, 2013, 22(1): 36-38.   doi: 10.13491/j.cnki.issn.1004-714x.2013.01.023
Zhang XY, Tu Y.  Dose distribution of radiation around human body in hyperthyroidism patients after 131I therapy[J]. Chin J Radiol Health, 2013, 22(1): 36-38.   doi: 10.13491/j.cnki.issn.1004-714x.2013.01.023
[16] Cui SY, Jiao L, Tan J, et al.  Estimating radiation absorbed dose of individuals nearby 131I-treated hyperthyroid patients[J]. Health Phys, 2014, 106(3): 365-369.   doi: 10.1097/HP.0b013e3182a1c8d5
[17] 康增寿, 李方, 林岩松.  开放性放射性核素治疗后患者免住院的建议(ICRP 94 报告要点解读)[J]. 国际放射医学核医学杂志, 2019, 43(5): 397-399.   doi: 10.3760/cma.j.issn.1673-4114.2019.05.002
Kang ZS, Li F, Lin YS.  Release of patients therapy with unsealed radionuclides (ICRP publication 94)[J]. Int J Radiat Med Nucl Med, 2019, 43(5): 397-399.   doi: 10.3760/cma.j.issn.1673-4114.2019.05.002